Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,829 Lymphoma
clinical trials

Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Thompson Oncology Group-Oak Ridge
mi
from
Oak Ridge, TN
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Health Central
mi
from
Ocoee, FL
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Ascension Mercy Hospital
mi
from
Oshkosh, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Rowan Regional Medical Center
mi
from
Salisbury, NC
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
PeaceHealth United General Medical Center
mi
from
Sedro-Woolley, WA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Ascension Providence Hospitals - Southfield
mi
from
Southfield, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
National Jewish Health-Northern Hematology Oncology
mi
from
Thornton, CO
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Essentia Health Virginia Clinic
mi
from
Virginia, MN
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Advanced Breast Care Center PLLC
mi
from
Warren, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Wheaton Franciscan Healthcare-Saint Joseph/Wauwatosa Campus
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
William E Kahlert Regional Cancer Center/Sinai Hospital
mi
from
Westminster, MD
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente-Woodland Hills
mi
from
Woodland Hills, CA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sanford Cancer Center Worthington
mi
from
Worthington, MN
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Wellspan Health - York Cancer Center
mi
from
York, PA
Click here to add this to my saved trials
Follicular Low Grade Non-Hodgkin's Lymphoma Clinical Trial
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin's Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Georgia Cancer Center at Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Status: Enrolling, Phase I
Updated: 12/31/1969
The Ohio State University Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling, Phase II
Updated: 12/31/1969
Northwell Health
mi
from
Manhasset, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Nebraska Medicine-Bellevue
mi
from
Bellevue, NE
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
North Shore Hem Onc Associates
mi
from
East Setauket, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
The University of Arizona Cancer Center at Dignity Health; St. Josephs Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cancer Treatment Centers of America-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Neoplastic Disease Clinical Trial
QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
Chan Soon-Shiong Institute for Medicine
mi
from
El Segundo, CA
Click here to add this to my saved trials
Gastroenterology, Immunology / Infectious Diseases, Oncology Clinical Trial
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (
Status: Enrolling, Phase II
Updated: 12/31/1969
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Status: Enrolling, Phase I
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Hodgkin's Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Status: Enrolling, Phase II
Updated: 3/3/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Hodgkin's Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Status: Enrolling, Phase II
Updated: 3/3/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Cancer Treatment Centers of America-Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mantle Cell Lymphoma (MCL) Clinical Trial
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Mantle Cell Lymphoma (MCL) Clinical Trial
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering West Harrison
mi
from
Harrison, NY
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma Clinical Trial
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling, Phase I
Updated: 12/31/1969
Washington University; Wash Uni. Sch. Of Med
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Lymphoma, Non-Hodgkin Clinical Trial
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
The Kinghorn Cancer Centre
mi
from
Darlinghurst,
Click here to add this to my saved trials
Oncology Clinical Trial
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
Fred Hutchinson/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Status: Enrolling, Phase I
Updated: 4/11/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
Merck Sharp & Dohme
mi
from
North Ryde,
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling, Phase II
Updated: 12/31/1969
Siteman Cancer Center at Saint Peters Hospital
mi
from
Saint Peters, MO
Click here to add this to my saved trials
Malignant Neoplasms Clinical Trial
A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Mary Crowley Cancer Research - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
Local Institution
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Sanford Broadway Medical Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Oncology Clinical Trial
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
GSK Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Status: Enrolling, Phase I
Updated: 12/31/1969
University of California, San Diego (UCSD) Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Status: Enrolling, Phase II
Updated: 12/31/1969
Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.
mi
from
Linz,
Click here to add this to my saved trials
Oncology Clinical Trial
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Enrolling, Phase I, II
Updated: 12/31/1969
PROCLAIM Investigative Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Enrolling, Phase I, II
Updated: 12/31/1969
PROCLAIM Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oncology Clinical Trial
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Enrolling, Phase I, II
Updated: 12/31/1969
PROCLAIM Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Enrolling, Phase I, II
Updated: 12/31/1969
PROCLAIM Investigative Site
mi
from
Madison, WI
Click here to add this to my saved trials
Oncology Clinical Trial
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Enrolling, Phase I, II
Updated: 12/31/1969
PROCLAIM Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Moores UC San Diego Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Pulmonary Lymphangioleiomyomatosis Clinical Trial
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Status: Enrolling, Phase II
Updated: 1/24/2018
Laboratory of Translational Research NHLBI
mi
from
Bethesda, MD
Click here to add this to my saved trials
Lymphoma, Non-Hodgkin Clinical Trial
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics
mi
from
Atlanta, GA
Click here to add this to my saved trials
Lymphoma, Non-Hodgkin Clinical Trial
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
New York Medical Center - NYU
mi
from
Valhalla, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hodgkin Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Hodgkin Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Status: Enrolling, Phase III
Updated: 12/31/1969
Merck Sharp & Dohme
mi
from
North Ryde,
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Brewer, ME
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Covington, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Farmington, NM
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Kinston, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Ogden, UT
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Clinical Trial
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Heidelberg,
Click here to add this to my saved trials
Hodgkin Lymphoma Clinical Trial
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Stony Brook
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Lymphoma, Mantle Cell Clinical Trial
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Buenos Aires,
Click here to add this to my saved trials
Lymphoma, Mantle Cell Clinical Trial
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Lymphoma, Mantle Cell Clinical Trial
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Lymphoma, Mantle Cell Clinical Trial
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Lymphoma, T-Cell Clinical Trial
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Center for Lymphoid Malignancies at CUMC
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Rochester Medical Center (URMC)
mi
from
Rochester, NY
Click here to add this to my saved trials
Hodgkin Lymphoma Clinical Trial
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Vanderbilt Dermatology
mi
from
Nashville, TN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
St Louis University Dermatology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Neoplasms Clinical Trial
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
Non-Hodgkin's Lymphoma Clinical Trial
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
1 … 89 90 91 92 93 94 95 96 97 98